Discontinued — last reported Q4 '23
MINJUVI — Total revenues
Incyte MINJUVI — Total revenues increased by 7.7% to $8.99M in Q4 2023 compared to the prior quarter. Year-over-year, this metric grew by 87.0%, from $4.81M to $8.99M. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market penetration and clinical adoption of the therapy, while a decrease may signal increased competition, patent expiration, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total gross revenue generated from the commercial sale of a specific oncology therapeutic pro...
Peer comparison
Comparable to product-specific revenue lines reported by other biopharmaceutical companies, often benchmarked against therapeutic area peers or direct competitors in the same oncology sub-segment.
incy_segment_minjuvi_total_revenuesHistorical Data
| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $556K | $4.35M | $4.5M | $4.41M | $5.93M | $4.81M | $6.56M | $13.16M | $8.35M | $8.99M |
| QoQ Change | — | +683.1% | +3.4% | -2.0% | +34.5% | -18.9% | +36.3% | +100.7% | -36.6% | +7.7% |
| YoY Change | — | — | — | — | +966.9% | +10.5% | +45.6% | +198.3% | +40.7% | +87.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's minjuvi — total revenues?
- Incyte (INCY) reported minjuvi — total revenues of $8.99M in Q4 2023.
- How has Incyte's minjuvi — total revenues changed year-over-year?
- Incyte's minjuvi — total revenues increased by 87.0% year-over-year, from $4.81M to $8.99M.
- What does minjuvi — total revenues mean?
- The total sales revenue generated by a specific drug product.